Expected to be in Clinical Trials 2018.

Expected to be in Clinical Trials 2018…
  • Vascustim – diabetic foot ulcer treatment.
  • HairCell – hair regeneration.
  • SkinStim – skin regeneration.
  • Second Heart Assist – circulatory assist support.
  • MilkStim – bioelectric milk production stimulation.
  • OrthoStim – joint recovery including inflammation reduction.
  • BioLeonhardt – heart regeneration.
  • Stem Cell Bra – breast tissue generation.
  • OrthodontiCell – bioelectric accelerated tooth movement and stabilization.
  • DentaCell – bioelectric + stem cells + PRF dental treatments.
Expected to be active Animal Studies in 2018..
  • EyeCell – eye regeneration.
  • BioLeonhardt – heart regeneration.
  • Valvublator – heart valve regeneration.
  • BioPace – pacemaker regeneration.
  • MyoStim ED – bioelectric erectile dysfunction treatment.
  • CancerCell – bioelectric cancer tumor eradication.
  • CerebraCell – brain regeneration.
  • PancreaCell – pancreas regeneration.
  • LiverCell – liver regeneration.
  • MucosaCell  – sub mucosa regeneration.
  • RegenaLung – lung regeneration.
  • BladderCell – bladder regeneration.
Leonhardt’s Launchpads 2017 Annual Review Letter to Shareholders
Playa Vista, California and Salt Lake City, Utah – February 15th, 2018
Dear Fellow Stakeholders, 
Leonhardt’s Launchpads had a very productive 2017 filled with significant achievements and progress and this hard work has positioned 2018 to be a breakout year likely with over 6 startups achieving first-in-man study results.  Below is a list of 2018 target goal milestones that our management team is intensely focused on achieving.
All of our product groups achieved significant progress in 2017.  Across all the startups we filed more than 100 new patent claims.  We raised more than $1.6 million in cash capital, secured approximately $500,000 in grant funding sourced over $3,000,000 in non-cash services for shares/options and leveraged over $100 million invested by our OEM manufacturers and technology partners on their own into the opportunistic end stage development of our products.  We filed a half dozen new grant applications and continued to advance forward grant funded studies for heart and eye regeneration.  We filed large scale NIH grant applications for BioPace and MyoStim ED which are still pending.
  • Heart & Cardiovascular (9)
  • Brain (1)
  • Cosmetic & Personal Care (7)
  • Major Organ Regeneration (11)
  • Cancer (1)
  • Regenerative Economy (3)
Heart & Cardiovascular 
Vascustim is moving the clinical HEAL registry study for treating diabetic foot and leg ulcers secondary to critical limb ischemia forward at multiple centers in the USA.   The Vascustim team working with two OEM vendors has FDA 510K market clearance for both benchtop and portable wound healing bioelectric stimulators.  Working with an experienced group in Utah Vascustim has secured supply sourcing of purified amniotic fluid membrane wound dressings legally available for sale in the USA under homologous exemption regulations.  BioLeonhardt is completing grant supported animal studies at the University of Utah.   An independent team in Austria and Germany published last year positive results in cardiac function improvement utilizing bioelectric stimulation in a heart failure model in animals which has increased attention to BioLeonhardt.  Working with our micro infusion pump technology partner Fluid Synchrony LLC of Pasadena, California we secured additional NSF SBIR grant funding for large animal studies forward.  Second Heart Assist completed large animal studies in 2017 at a leading U.S. institution and is poised to enter OUS clinical studies in 2Q 2018 to be followed by a U.S. FDA Early Feasibility Study later in the year. The team has a pre-sbumission Early Feasibility Meeting study meeting with the FDA in Washington D.C. in early January. The Second Heart Assist 2nd generation wireless chronic implant is expected to have lab test results from Australia this early spring.  The Second Heart Assist team filed dozens of its own new patent claims recently and also signed a patent option license agreement with Caltech  for additional patents. BioPace is advancing research forward at U of Utah working with Dr. Alonso Moreno and is applying for grant funding with multiple agencies as well as new patent applications.  PressureStim filed numerous patent claims for bioelectric blood pressure control.   Valvublator filed a number of new patent claims is currently building out test prototypes of its heart valve decalcification and regeneration devices.   AortaCell is doing the same for aorta regeneration.  BioLeonhardt, Second Heart Assist and Valvublator presented a a dozen major meetings including TCT Denver, CRT D.C., The World Congress of Cardiology, Interventional Cardiology Snowmass, Cardiovascular Regeneration at Texas Heart Institute and DHF Berlin.   Second Heart Assist, Inc. and BioLeonhardt have made it through the sem-finals of the American College of Cardiology and AngelMD National Innovation Challenge and are in the running to be one of the 4 finalists invited to the ACC Annual Meeting in Orlando March 11th to present.
CerebraCell launched a research collaboration with Dr. Santosh Kesari Director of Research at the Pacific Neurosciences Institute in Santa Monica and has secured access to research lab space there.  Dr. Warren Merrifield was recruited at Chief Technology Officer.  Dr. Lina Nih from the UCLA Brain Research Institute joined us as a consulting advisor as did Mo Farhoud.   The team designed a new non-invasive cerebral stimulation helmet.   Research collaboration discussions have been launched with MIT related to temporal interference based non-invasive deep brain stimulation.  CerebraCell filed a number of new patent claims in 2017 including those related to reading and managing chronic inflammation with bioelectric signaling.
Cosmetic and Personal Care 
OrthdontiCell completed animal and protein expression lab studies at our lab in Utah for accelerated tooth movement and stabilization and has moved onto a definitive animnal study at Forsyth Institue in Boston which should be completed by March. We believe our patent pending bioelectric stimulation sequence will reduce brace an aligner time from 18 months to 6 months and will keep teeth straight without retainers after straightening.    We intend to enter clinical trials this spring.   Stem Cell Bra has moved onto its second round of large animal studies in Argentina we achieved 20% to 30% breast tissue volume growth with only 1 hour stimulation every other day in our previous study.  We hope to move into clincial trials later this year.  DentaCell has expanded into DentaCell Accelerator has has recruited an all-star advisory board to advance forward bioelectric, stem cell, growth factor and personalized medicine therapies in dentistry. Dr. Maryann Chalmers has joined DentaCell whom has a number of frequency specific patents related to dental procedures.  Dr. Val Kanter has joined as Chief Scientific and Medical Officer.  Tom Newman as President.   SkinStim for skin regeneration is moving into clinical trials and has hired Chris Rosgen as President.  MyoStim ED applied for NIH grant funding erectile dysfunction recovery working with UCLA and Dr. Nestor Gonzalez-Cadavid.  The team has sourced organ interface intelligent textiles from Prizm Medical in Georgia. HairCell is moving into clinical trials in Canada and has teamed with TeslaBrush of Canada and an amniotic fluid source team in Utah and a PRF team in Florida.   MilkStim completed large animal studies in Argentina for bioelectric milk production stimulation.  A 20% increase in milk production was achieved in early stage studies.   The team is planning to repeat studies this summer in California.
Major Organ Regeneration 
EyeCell completed successful cadaver eye studies in Utah and is now in the middle of a controlled animal study at the University of Utah with grant funding support.   PancreaCell made it to the finals of the American Diabetes Association National Innovation Pitch Contest and presented at their annual meeting in San Francisco.  PancreaCell is preparing grant applications with the University of Miami Diabetes Research Institute and the University of Arizona. It previously filed a grant application in Utah with USTAR.  RegenaLung developed the ECMOCath and is advancing towards animal studies for lung regeneration.  LiverCell opened research discussions with Duke University and is preparing research grant applications.   KidneyCell filed a number of new patent claims,.  EarCell filed new patent claims and upgraded their web site.  BladderCell is preparing for animal studies.  MucosaCell teamed up with Dr. Stuart Williams at the U of Louisville to advance forward research.  InStim filed a number of new patent application claims for reading inflammation and then custom delivering precise infllammation control bioelectric signals.  BioLeonhardt Whole Body held research discussions with the National Science Foundation and is preparing a granbt application.  The team also sourced a conductive yoga and athletic body suit and prepared for the introduction of Bod-Stim the first wearable rejuvenating suit.  OrthoStim is launching a product platform for bioelectric, PRF and stem cell based composition treatment of joint disorders including arthritis.
CancerCell filed a number of patent claims for treating cancer tumors including claims for custom jamming communication signals of cancer tumors, starving cancer tumors of blood supply,  stopping cell division, changing surface proteins of a tumor to get the person’s own body to attack it (immuno therapy), changing surface electric charges of tumors and managing inflammation and its relationship to cancer.  We have entered discussions with some leading cancer researchers and funding sources about collaboration.  We entered a patent license agreement with Neuro Code Tech Holdings for a series of patents they have related to bioelectric cancer tumor reading and customized treatments.
Regenerative Economy 
The California Stock ExchangeTM continues to explore partnerships for launching the first social good impact stock exchange in the USA.  Cal-X Crowdfund Connect is building numerous bridges to crowdfunding resources.   Food Trikes & Scooters is working on securing a financing partner.   Lionheart Brands Marketing Cooperative is building a business and marketing plan. We still have 90 cases of our 2012 Leonhardt Vineyards Cabernet Sauvignon in stock which was produced in Sonoma County. Wine Country Baseball prepares for its 9th Annual Wine Country Baseball Classic. Lucille’s American Cafe’s seeks franchise buyers based on the success of its flagship restaurant in Weston, Florida. Kindheart Lionheart Media & Publishing continues to advance forward the screenplay for Dolphin Smiles:   The Legend of Kindheart Lionheart.  The Kindheart Lionheart TV Network our inspiration al works TV network  www.kinddheartlionhearttv.com has over 2 billion views across all programs and is developing a plan to secure advertisers.  Network original programming California Love, Love Dialogues, Lions Den, Love Roller Coaster, Covers of Great Speeches, Dolphin Smiles: The Legend of Kinhdeart Lionheart continue to advance forward with a number of scripts written and ready.  The Love Roller Coaster pilot episode was finished, aired and was well received.
We now employ directly 8 biomedical engineers most of them working out of our lab in Utah.  We have over 144 experienced management team, board and advisory consultant members – https://leonhardtventures.com/team/ +  https://calxstars.com/scientific-advisory-board/ that provided over $3,000,000 worth of services in 2017 in exchange for share options. Our implantable micro stimulator OEM manufacturer invested over $50 million into the development of the micro stimulator the supply to us that is programmed with our patented and patent pending bioelectric signals and sequences.  Our bench top stimulator provider has U.S. 510K market clearance as does our mobile portable stimulator provider which includes FDA market clearance for conductive textile organ interfaces.  Our micro infusion pump partner has received over $2.1 million of NSF SBIR grant funding to develop that device.  Our OEM manufactuer for catheters including the Second Heart Assist, Inc. devices has invested multiple millions into their infrastructure and team at the cGMP manufacturing facilities in Utah and Minnesota.  Our BioInnovations Gateway Lab in Utah with USTAR support has access to over $100 million of research equipment, infrastructure and personnel and over 7 USTAR locations including a complete NanoFabrication facility and mulitple resources for prototype building and testing.
In 2018, Leonhardt’ Launchpads startups are expected to carry out up to 8 clinical trials advancing forward organ specific regeneration and recovery technologies through first-in-man data and positioning at least 6 of these startups to be prime ripe to secure a strategic partner/buyer and forward royalty agreements.   2018 and 2019 ahead should be great years for our organization. Thank you all for your continued support!
Howard J. Leonhardt
Executive Chairman and Chief Executive Officer
Brief Elevator Pitches about our Startups are published here on our web site – 
The current valuations of our startup is published here – https://leonhardtventures.com/our-companies/#toggle-id-2 ;
Leonhardt’s Launchpads by Cal-X Star Business Accelerator, Inc. 
2017 Brief Summary Achievements 
Patents = Over 100 new patent claims filed.  Over 50 new patent claims licensed.  Covering organ regeneration, circulatory assist support, accelerated tooth movement and stabilization, inflammation control, blood pressure control, biological pacing, heart valve decalcification,vibrational harmonic resonance for stopping blood clots, plaque and calcification on blood contact surfaces, bioelectric cancer treatment.  Our bioelectric signals patented and patent pending now include SDF-1, IGF-1, HGF, EGF, PDGF, VEGF, HIF1a, Activin A+B, IL1,6,9, Follistatin, Tropoelastin, CXCR5L, RANKL, OPG, TGFb, cancer detection and tumor growth stoppage, inflammation monitoring and control, blood pressure monitoring and control.   SDF-1 + PDGF are stem cell homing signals.  We also have signals for stem cell proliferation and differentiation control.   Patent license agreements were concluded with Caltech (circulatory assist support) and Neuro Code Tech Holdings LLC (bioelectric cancer and blood pressure treatments).  Patent license agreements are in process with Queensland University (wireless power repeater), Minnetronix (wireless power), Ohio State (bioelectric healing patch) and MIT (non-invasive deep organ stimulation).
R&D = Built and tested dozens of bioelectric stimulation devices, organ interfaces, micro infusion pumps and circulatory assist devices.  Created partnership with amniotic fluid and amniotic membranes supplier in Utah.
Key Partnerships:  Caltech, Queensland U, Tufts U, U of Louisville for Second Heart Assist.  U of Utah for BioLeonhardt, OrthodontiCell, BioPace and EyeCell.  UCLA for MyoStim ED, Stem Cell Bra, CerebraCell and Orthodonticell.  USC for Vascustim and Valvublator, Miami Cardiac & Vascular Institute for Vascustim, AortaCell, PressureStim and Valvublator.  U of Louisville for MucosaCell, BioLeonhardt.  U of Arizona for PancreaCell and Vascustim.  Forsyth Institute for OrthodontiCell.  UCSF and Tufts U for Orthodonticell.  Numerous centers for DentaCell Accelerator.  Duke U for LiverCell.   Mayo Clinic for RegenaLung and BladderCell.  Donovan Medical Vancouver for HairCell.  Centeno-Schultz Colorado for InStim and more.  WearTech Therapeutics/Prizm Medical for conductive textiles and portable stimulators – all startups, Mettler Electronics for bioelectric stimulation external.   QIG Greatbatch for implantable micro stimulators.  Fluid Synchrony LLC for micro infusion pumps.  Prizm Medical for wearable stimulators.
People = Over a dozen key advisors added to team including Dr. Mark Kroll former CTO of St. Jude Medical.  5 bioengineers now working in our own Utah lab.
Opinion Leader Engagement =  Added a dozen key opinion leaders to various advisory boards.  We presented at over a dozen major conferences.
Grants and Funding Contests:   Filed 5 grant or funding applications = MyoStim ED, CerebraCell, Second Heart Assist, PancreaCell, BioPace.  PancreaCell made it to national finals of American Diabetes Association startup pitch contest.  MyoStim ED and BioPace NIH grant applications are still pending potential award.
Data = Utah lab team bioelectrically stimulated over 200 animal, cell dishes and cadaver specimens and gathered data from all these experiments.  Our affiliated Genovese lab in Argentina also stimulated over 300 animal, cell and cadaver specimens and gathered data on each.  Our Second Heart Assist team completed over two dozen lab tests and 4 large animals.
Capital Raising:  We raised $1.6 million in capital in 2017 ($400,000 from Fluid Synchrony LLC which as deposited back with them towards future work and purchases).
Marketing:  We created over a dozen new web sites and upgraded over 35 web sites.  All web sites include a compilation of dozens of supporting scientific articles.  Slide decks were created for 15 of our 30 startups.  We have over 20 animation and live action videos to support our startups created in partnership with Gas Money Productions in Burbank, CA and Drewsy Media in Glendale, CA.
2018 Goals 

Leonhardt‘s Launchpads by Cal-X Stars Business Accelerator, Inc.

201Portfolio of Startups/Licensable Technology Platforms (LTP’s)
Regenerative Medtech – Organ Regeneration 
  • BioLeonhardt – heart regeneration = complete animal studies and launch OUS clinical study > find strategic partner. 
  • AortaCell – aorta regeneration = complete animal studies. 
  • BioPace – biological pacemaker regeneration = complete animal studies. 
  • Valvublator – heart valve regeneration =  finish prototype development and lab studies and launch animal studies. 
  • VibroCell (includes CoroStim) – vibrational energy to prevent clots, plaque, calcification = finish prototype development and lab studies + complete animal studies. 
  • HeartScore – genomics and bioelectric based heart failure, inflammation and stroke management = find strategic partner. 
  • VascuStim (formerly MyoStim Peripheral, includes EndoCell) – limb salvage regeneration, blood flow improvement for critical limb ischemia, diabetic leg and foot ulcer treatment, artery regeneration = complete international registry clinical study with multiple arms > find strategic partner. 
  • Second Heart Assist, Inc. – wireless powered chronic or temporary circulatory assist pump in aortic stent = complete animal studies and first-in-man studies for catheter 1st gen. device > find strategic partner.   Complete lab and animal studies 2nd gen. wireless power. 
  • PressureStim – bioelectric treatment of high blood pressure via improved arterial elasticity and bioelectric membrane potentials management = complete animal studies. 
  • CerebraCell (includes CerebraCell Brain-N-Hance and CerebraCell Concussion) – brain regeneration, cognitive function improvement, concussion recovery = complete lab and animal studies. 
  • Stem Cell Bra – breast regeneration = finish 2nd round of large animal studies.  Launch first-in-man studies > find strategic partner. 
  • DentaCell Accelerator – dental gum regeneration + tooth pulp storage = launch tooth pulp storage business, develop new dental innovations & startup. 
  • OrthodontiCell – bioelectric stimulator for accelerated tooth movement and freezing teeth positions straight = complete animal studies, complete first-in-man studies > find strategic partner. 
  • SkinCell Stimulator by MyoStim Skin – skin regeneration = launch OUS first-in-man studies. 
  • MyoStim ED – bioelectric erectile dysfunction treatment = complete animal studies + launch OUS first-in-man studies. 
  • HairCell – hair regeneration = launch OUS first-in-man studies > find a strategic partner. 
  • MilkStim – bioelectric breast milk production stimulation.  = finish animal studies > launch in vet market > launch human clinical studies .
  • EyeCell – eye regeneration = complete small and large animal studies. 
  • PancreaCell – pancreas regeneration = complete animal studies. 
  • RegenaLung (includes ECMO-Cath) – lung regeneration (includes 50% owned subsidiary RegenaLung COPD) cannula for infusing oxygen directly into the blood using an oxygenator, a medical device that acts as an artificial lung = find research partner + complete animal studies
  • LiverCell – liver regeneration = find a research partner (DUKE?) + complete animal studies. 
  • KidneyCell – kidney regeneration =  find a research partner + complete animal studies. 
  • EarCell – ear hearing regeneration = find a research partner + complete animal studies. 
  • BladderCell – bladder regeneration = find a research partner + complete animal studies. 
  • MucosaCell – sub-mucosa regeneration = complete animal studies. 
  • InStim – bioelectric real time inflammation management = develop prototype + complete animal studies. 
  • OrthoStim – bioelectric joint recovery treatment = conduct clinical registry study USA
  • BioLeonhardt Whole Body Regeneration – whole body regeneration and Bod-Stim bioelectric yoga and athletic pants = secure SBIR grant add CIP claims to patent + build and test body suit prototypes. 
  • CancerCell – bioelectric cancer tumor treatment + regeneration = complete lab + animal studies and launch first-in-man studies OUS > find strategic partner. 
Regenerative Economy
  • The California Stock ExchangeTM  (includes Cal-X Crowdfund Connect) – Alternative financing tools for social good impact and life science cos = secure a strategic partner. 
  • Kindheart Lionheart Media & Publishing – Social good impact and life science media = hire ad sales manager + add new content + complete pilots of original series (4). 
  • Leonhardt Food & Beverage – Social good impact and life science research fund raising via beverage, food and related support services = launch Lionheart Marketing Cooperative. 
  • Leonhardt Accelerators & Incubators – Social good impact and life science innovation & startup incubators and accelerators in California and Utah = Find strategic partners for 6 startups.  Gather supporting animal data on a dozen products.  Gather supporting clinical data on 6 products.  File over 30 new patent claims.  Gather opinion leader endorsements 12+.  Get positive press coverage. 
Leonhardt’s Launchpads by Cal-X Stars, 12655 W Jefferson Blvd, Los Angeles, CA 90066
Leonhardt Ventures LLC, 12760 Millennium Dr. A213, Play Vista, CA. 90094

Leonhardt’s Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84111

Google Voicemail All Locations:  
Leonhardt’s Launchpads NorCal @
University of Northern California
Science & Technology Innovation Center (UNC STIC)
1129 Industrial Ave, # 207
Petaluma, CA 94952


Leonhardt’s Launchpads Utah, Inc. 
@ C&S Business Incubator
370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 
BioInnovations Gateway
2500 S State St. #224, Salt Lake City, UT 84115 –
Google Voice Mail for ALL locations:  (424) 291-2133
Disclaimer Regarding the Term “Companies or Startups” Used in our Materials:  In our accelerator and incubator terminology “companies or startups” often refers to a new innovation being developed with full intention to form a separate spin out company IN-THE-FUTURE when the innovation has completed mentored incubated development into a full fledged organization with a web site, slide deck, basic business plan, board, team and has gotten some marketplace traction, including independent funding or revenues, to commence operations as a stand alone independent separately legally formed corporation.  We DO NOT file “startups” to become independent separate legal entity “C or S corporations” until they are at an advanced stage of development and are deemed by our board or lead management to be ready to survive on their own.  All early stage seed “companies” within the accelerator/incubator share the same accelerator or venture fund checking account, accounts payable and receivable clerks, accountants, lawyers, web site developers, support staff, consultants, advisory board, conference rooms, offices, telephone systems, internet wifi accounts and even management personnel until they are advanced enough with a dedicated focused team in place with strength enough to be pushed out of the next to fly on their own and feed themselves (get their own independent funding).  We avoid filing to early stage “companies” to be independent stand alone legally registered ” C or S corporations” until they are truly deemed to be fully ready to be self reliant.  This avoids un-necessary legal fees associated with city, county, state and federal filings.  So until they are legally spun out as a separate entity these “companies” or “innovations” are officially product innovation development teams or projects under the Cal-X Stars Business Accelerator, Inc. or Leonhardt Vineyards LLC DBA Leonhardt Ventures umbrella organizations.  Our Private Placement Memorandum for Cal-X Stars Business Accelerator, Inc. published on the password protected site (reserved for verified accredited investors only) provides clear guidance on which “companies” have moved from being internal or external innovations under development into full fledged separate stand alone legal entities.

Accuracy of Information Disclaimer:  Representations and warranties – although we fully believe that our executive summaries, newsletters, websites and other written materials and videos accurately represent a true and accurate general high level picture of our activities, history and progress – which is developing about 15 early stage un-proven cardiovascular life innovations and 15 early stage startup social good impact innovations (including new media social good projects) in an accelerator/incubator – we acknowledge that working with a very small core staff covering many thousands of pages of written materials across over 40 web sites with over 4000 sub-pages that we are highly prone to small errors, outdated materials and a certain level on inaccuracy and inconsistencies even while fully striving for the utmost accuracy.  Across the 30 innovations and over 2000 working partnerships being developed there are changes and events that occur almost daily.  We do our best to keep all websites and published materials fully up to date but recognize and make clear it is nearly impossible for our small staff to keep all materials on all web sites 100% up to date despite our best efforts to do so.  Investors have the advantage with us that our small staff operates with a very low overhead but the offset disadvantage is that we do not have on hand the staffing to handle all the constant updates and proofreads needed to keep thousands of pages of materials up to date and 100% accurate 100% of the time.  If you have ANY direct question about any published item of material interest to you – JUST ASK for clarification by emailing direct Howard Leonhardt at hleonhardt@aol.com or calling our office DIRECT LINE at   (424) 291-2133 We will strive to provide a clarification or update to you promptly.

Financial Update
As of December 31, 2017, Leonhardt’s Launchpads and its startups had $900,000 in cash and cash equivalents, bank deposits, restricted deposits with vendors ($400,000 on deposit with Fluid Synchrony LLC for engineering and micro pump infusion device supply forward) and marketable securities. The Company’s approximate (final year end statements still in CPA review closing process) net cash used for operating activities for the quarter ended December 31, 2017 was $265,000.   The company has received over $500,000 in grant funding from various sources working with research and technology development partners such as Fluid Sychrony LLC. 
About Leonhardt’s Launchpads:  
Leonhardt’s Launchpads is the innovation and startup accelerator arm of Leonhardt Ventures and Howard J. Leonhardt.  The accelerator(s) have research and office operations in Northern and Southern California as well as Utah.   Currently 32 startups and separate innovations are being accelerated across the three locations.   The focus o the accelerator is organ regeneration and recovery with a small unit working on creating short term revenues from regenerative economy startups with the profits process intended to finance non-dilutive organ research and recovery technology research.   The lions share of these startups are all based on Leonhardt’s core patented and patent pending technology of a bioelectric stimulator + a micro infusion pump + a fifteen component organ regeneration composition.  Most the the core IP relates to specific bioelectric signals for specific protein expressions for specific purposes such as a stem cell homing signal, inflammation management, improving blood circulation or tissue regeneration.
Safe Harbor Statement
This letter contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of Leonhardt’s Launchpads only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Leonhardt’s Launchpads and its startups may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristem’s products may not be approved by regulatory agencies,  Leonhardt’s Launchpads technologies may not be validated as it progresses further and its methods may not be accepted by the scientific community; Leonhardt’s Launchpads may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Leonhardt’s Launchpads process; Leonhardt’s Launchpads products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Leonhardt’s Launchpads patents may not be sufficient; Leonhardt’s Launchpad’s products may harm recipients; changes in legislation may adversely impact  inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Leonhardt’s Launchpads to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Leonhardt’s Launchpads undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Leonhardt’s Launchpads reports posted from time to time on its web sites, in press releases, at meetings or with various regulatory agencies.